Optimal adaptive two-stage designs for phase II cancer clinical trials
From MaRDI portal
Publication:2858002
DOI10.1002/BIMJ.201200220zbMATH Open1441.62339OpenAlexW1914095056WikidataQ51184477 ScholiaQ51184477MaRDI QIDQ2858002FDOQ2858002
Authors: Stefan Englert, Meinhard Kieser
Publication date: 19 November 2013
Published in: Biometrical Journal (Search for Journal in Brave)
Full work available at URL: https://doi.org/10.1002/bimj.201200220
Recommendations
- Adaptive two-stage optimal designs for phase II clinical studies that allow early futility stopping
- Adaptive Two-Stage Designs for Single-Arm Phase IIA Cancer Clinical Trials
- Improving the flexibility and efficiency of phase II designs for oncology trials
- Designs for Group Sequential Phase II Clinical Trials
- Adaptive clinical trial designs for phase I cancer studies
Cites Work
Cited In (17)
- Optimal exact design of double acceptance sampling plans by attributes
- Two-stage design for phase II oncology trials with relaxed futility stopping
- MULTINOMIAL PHASE II CANCER TRIALS INCORPORATING RESPONSE AND EARLY PROGRESSION
- Improving the flexibility and efficiency of phase II designs for oncology trials
- Exact confidence limits after a group sequential single arm binary trial
- On optimal subset designs for phase II clinical trials with both total response and disease control
- Random norming AIDS analysis of non-linear regression models with sequential informative dose selection
- Adaptive Two-Stage Designs for Single-Arm Phase IIA Cancer Clinical Trials
- Bayesian enhancement two-stage design with error control for phase II clinical trials
- Optimal planning of adaptive two-stage designs
- A batch‐effect adjusted Simon's two‐stage design for cancer vaccine clinical studies
- Bayesian adaptive two-stage design for determining person-time in phase II clinical trials with Poisson data
- Randomized phase II cancer clinical trials
- New results on optimal conditional error functions for adaptive two-stage designs
- Adaptive two-stage optimal designs for phase II clinical studies that allow early futility stopping
- Adjusting Simon'S optimal two-stage design for heterogeneous populations based on stratification or using historical controls
- An optimal design in a two-stage ethical allocation based on U-statistics
This page was built for publication: Optimal adaptive two-stage designs for phase II cancer clinical trials
Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q2858002)